{"url":"https://newsforagent.com/news/2026-11-07/organon-va-hadlima-switchback-study","markdown_url":"https://newsforagent.com/news/2026-11-07/organon-va-hadlima-switchback-study.md","title":"Organon VA Study Shows 1.3% HADLIMA Switchback Rate","headline":"Organon Reports 1.3% Switchback Rate in VA HUMIRA-to-HADLIMA Switch Study","description":"Organon's VA study found a 1.3% switchback rate over 12 months after the HUMIRA-to-HADLIMA formulary switch.","section":"Research & Clinical Trials","published_at":"2026-11-07T15:46:37+00:00","modified_at":"2026-11-07T15:46:37+00:00","author":"News Desk","key_takeaways":["Organon reported a 1.3% switchback rate over 12 months in a VA system-wide switch from HUMIRA to HADLIMA.","Average per-patient pharmacy costs fell by $8,100 in the first year, and adherence remained similar pre- and post-switch.","The VA selected HADLIMA for its national formulary in 2024, so the study evaluates an existing decision rather than a new contract.","Sun Pharmaceutical Industries agreed in April 2026 to acquire Organon for approximately $11.75 billion, a deal expected to close in early 2027."],"companies":[{"name":"Organon","is_primary":true,"profile_url":"https://akta.pro/company-profiles/0000fga/organon","website":"https://www.organon.com"}],"source":{"publisher":"TradingView","title":"Organon (OGN) Reports 1.3% HADLIMA Switchback Rate in VA Study","url":"https://www.tradingview.com/news/tradingview:391ac7341c4be:0-organon-ogn-reports-1-3-hadlima-switchback-rate-in-va-study/"},"other_sources":[],"tags":["Research & Clinical Trials","Organon"],"body_markdown":"[Organon](https://akta.pro/company-profiles/0000fga/organon) reported a 1.3% switchback rate over 12 months in a VA system-wide switch from HUMIRA to HADLIMA, with average per-patient pharmacy costs falling by $8,100 in the first year. The findings were published by [TradingView](https://www.tradingview.com/news/tradingview:391ac7341c4be:0-organon-ogn-reports-1-3-hadlima-switchback-rate-in-va-study/). Organon is a global pharmaceutical company that develops and commercializes 70+ medicines and medical devices across women's health, biosimilars, and established brands, serving patients and prescribers in 140+ markets worldwide.\n\n## Inside the VA Switchback Findings\n\nThe study tracked the VA's system-wide move from HUMIRA to HADLIMA and found that 1.3% of patients switched back over 12 months. Adherence remained similar before and after the switch, and average per-patient pharmacy costs fell by $8,100 in the first year. No prior-period cost comparison was provided. The release cites published switchback rates of 16–18%. The VA selected HADLIMA for its national formulary in 2024, so the study evaluates an existing formulary decision rather than announcing a new customer or contract.\n\n## Organon's Biosimilar and Deal Record\n\nAccording to akta.pro [company records](https://akta.pro/company-data), Organon completed a global licensing agreement with Sebela Pharmaceuticals in June 2026 for exclusive rights to MIUDELLA, a hormone-free copper IUD, with commercial launch expected in late 2026. In May 2026, the FDA approved expanded indications for TOFIDENCE (tocilizumab-bavi biosimilar) to include CAR T cell-induced cytokine release syndrome in adults and pediatric patients 2+ years, and hospitalized COVID-19. Sun Pharmaceutical Industries entered a definitive agreement in April 2026 to acquire Organon for approximately $11.75 billion, or $14.00 per share in an all-cash deal at a roughly 24% premium, expected to close in early 2027, after which Organon would be delisted from the NYSE.\n\n## Earlier Organon Research and Earnings\n\nOn November 5, 2026, Stock Titan reported that Organon will present a pooled post-hoc analysis of Phase 3 data on VTAMA cream at the ACAAI meeting on November 14, 2026, evaluating efficacy consistency across atopic dermatitis subgroups based on baseline BSA and other characteristics. On October 30, 2026, TradingView reported that Organon's third-quarter 2026 revenue was $1.57 billion, down 1.7% year-over-year, while net income rose 2.5% to $164 million and diluted EPS was $0.6 versus $0.61 a year earlier. On October 22, 2026, Business & Financial reported that DelveInsight's 2026 endometriosis pain pipeline report covers emerging therapies from companies including Organon, Ironwood, and AbbVie.\n\n## What Comes Next for Organon\n\nThe VTAMA analysis is scheduled for presentation at the ACAAI meeting on November 14, 2026. The Sun Pharmaceutical acquisition is expected to close in early 2027, and the MIUDELLA commercial launch is expected in late 2026.\n","publisher":{"name":"News for Agent","url":"https://newsforagent.com"}}